WO2006007676A1 - Combination of active fractions from the plants euphorbia tirucalli l and ficos carica l. and method of treating cancer and aids - Google Patents

Combination of active fractions from the plants euphorbia tirucalli l and ficos carica l. and method of treating cancer and aids Download PDF

Info

Publication number
WO2006007676A1
WO2006007676A1 PCT/BR2004/000127 BR2004000127W WO2006007676A1 WO 2006007676 A1 WO2006007676 A1 WO 2006007676A1 BR 2004000127 W BR2004000127 W BR 2004000127W WO 2006007676 A1 WO2006007676 A1 WO 2006007676A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
combination
plants
ficus carica
euphorbia tirucalli
Prior art date
Application number
PCT/BR2004/000127
Other languages
French (fr)
Inventor
José Maria Morais DIAS
Cláudio Paulino CHAVES
Original Assignee
Amazônia Fitomedicamentos Ltda.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amazônia Fitomedicamentos Ltda. filed Critical Amazônia Fitomedicamentos Ltda.
Priority to PCT/BR2004/000127 priority Critical patent/WO2006007676A1/en
Publication of WO2006007676A1 publication Critical patent/WO2006007676A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Definitions

  • the present invention refers to the combination of active fractions from the plants Euphorbia tirucalli L. e Ficus carica L, more particularly the pharmaceutical compositions comprising the said combinations, which are useful for treatment of cancer and Acquired Immunodeficiency Syndrome (AIDS).
  • the present invention also relates to the process of manufacture of the active fractions from the plants.
  • the present invention relates to the combination of active fractions from the plants Euphorbia turicalli L. and Ficus carica L, useful for treating cancer and AIDS, which not causes physicals and/or psychological damages to patients.
  • the Euphorbia turicalli L is a member of the Euphorbiaceae family, native from Oriental Africa and Asia, also known as "aveloz”, “esquleto”,
  • the plant includes the following chemical compounds: 12-o-(2Z)(4E)-octadienol-4- deoxyphorbol-13-acetate, 3,3'-di-o-methylellagic-acid, beta-sitosterol, citric acid, ellagic acid, euphol, euphorone, glucose, hentriacontane, hentriacontanol, isoeuphoral, kamepferol, malic acid, resin, sapogenine acetate, succinic acid, taraxasterol, taraxerin and tirucallol.
  • the latex obtained from the plant Euphorbia tirucalli L is toxic, irritant and caustic.
  • the sap milky can cause lesion and edema on skin and mucous, irritation, eyes tearingly, edema of eyelids and even though vision difficult.
  • the latex ingestion may also cause nausea, vomits, diahea and some amounts can be fatal.
  • Ficus carica L is a member of the Moraceae family, native from Asia (Mediterranean region), also called fig and "figo roxo".
  • the plant includes the following chemical compounds: araquidic acid, ascorbic acid, boric acid, citric acid, fumaric acid, glutamic acid, linoleic acid, linolenic acid, malic acid, oleic acid, oxalic acid, pantothenic acid, quinic acid, succinic acid, arabinose, arginine, carbohydrates, beta-carotene, chlorophyll cystin, fitosterols, fructose, glycine, glucose, histidine, isoleucine, leucine, lutein, mucilage, pectin, protein, riboflavin, mineral salts (boron, calcium, copper, phosphorus, potassium and zinc), serine, sucrose, valine, vitamin B6 and the leafs contain furanocumarines.
  • Euphorbia tirucalli L and Ficus carica L comprise the steps: a) dissolution of the latex obtained from Euphorbia tirucalli L in water until the concentrations of about 1 ppm to about 10,000 ppm at neutral pH; b) decoction of the leafs from Ficus carica L in water until the concentrations of about 0.1 to about 10%, preferably about 2,5%, inducing and keeping the heating until the temperature of about 70 to 100 0 C for about 20 to 30 minutes and after cooling by a natural or induced process; c) filtering the product of b) to remove the impurities or solid residues; d) dissolution of the product of c) until concentrations of about 20% to about 40%, preferably about 30% at little acid pH; and e) mixing the active fraction obtained in a) and d) steps.
  • the active fractions obtained by (1) and (2) are combined in ratio ranges varying from about 2:1 to about 2:100 or from about 2:1 to about 100:1 respectively and should comprise pH limits varying from about 2 for the concentrated product to about 7 for the diluted product.
  • the active fractions combined according to the invention are useful in the treatment of Cancer and AIDS and present analgesic activity, antioxidant, anti-inflammatory, anti rheumatic, emetic, immunessupressor, rubefacient, hipoglicemiant, expectorant, digestive and depurative. Moreover, it can be used internally against scorpions and snakes bites and externally in warts, rheumatic ache, physical damages, asthma, cough, and insects repellent.
  • the combination of active fractions according to the invention does not present adverse effects of the plant Euphorbia tirucalli L.
  • the combined product also provides the acceleration of the treatment process if compared to the traditional treatments.
  • the present invention also describes pharmaceutical compositions comprising at least one of the active fractions of the plants Euphorbia tirucalli L and Ficus carica L. or their combination together with pharmaceutical acceptable carriers.
  • compositions according to the present invention may contain about 0.001% to about 5% by weight of the active fraction from Euphorbia tirucalli L and about 0.001% to about 50% by weight of the active fraction of Ficus carica L..
  • compositions according the present invention may be administered by orally (immediate or sustained release forms), parenterally
  • intramuscular endovenous, intraarteral, intraperitoneal, intrathecal, subcutaneous, hypodermic or intradermic forms
  • mucosally pulmonary, sublingual, nasal, conjuctival, rectal or vaginal formsmucosally or topically.
  • the appropriated forms includes all the forms known in the art, such as solutions, suryps, suspension, emulsion, lotion, cream, gel, aerosol, tablet, capsule, pellets and other.
  • the pharmaceutical acceptable carriers according to the invention may include all known in the art, such as lactose, glucose, methyl cellulose, magnesium stearare, dicalcium phosphate, calcium sulphate, manitol, sorbitol, ethanol, glycerol, water and similar.
  • composition according to the invention may include as necessary one or more pharmaceutical additives, such as agglutinants, lubrificants, desintegrants agents, color agents and other.
  • pharmaceutical additives such as agglutinants, lubrificants, desintegrants agents, color agents and other.
  • the present invention refers to the use of the combination of active fractions in the manufacture of a medicament or pharmaceutical composition useful in treatment of cancer or AIDS.
  • the present invention also refers to the method of treating cancer and AIDS by the administration of the combination of active fractions from the plants Euphorbia tirucalli L and Ficus carica L. or the administration of the pharmaceutical compositon comprising said active fractions mentioned above.
  • the following example illustrates a particular embodiment of the invention without any limitation.
  • the active fraction of Euphorbia tirucalli L was gotten becoming fluid 0,5ml of the latex extracted of the plant in 1 liter of water (concentration of the solution 436,35ppm, or either, 0,43635g of the latex for one 1 kg of solution). pH measured in the diluted product was 7,12.
  • the active fraction of Ficus carica L was prepared weighing initially 25g of leves of the related plant, placing them on decoction in 1 liter of water until the temperature of 70 0 C and remaining superior temperature 70 0 C for about 25 minutes (maximum temperature reached 98-100 0 C). After that the gotten cool and filtered product. The gotten intent product then was diluted with water 30% (300 ml_ of product concentrated for 1 liter of water). pH measured in the diluted product was of 5,43.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention refers to the combination of active fractions from the plants Euphorbia tirucalli L. e Fícus carica L. more particularly the pharmaceutical compositions comprising the said combinations, which are useful for treatment of cancer and Acquired Immunodeficiency Syndrome (AIDS). The present invention also relates to the process of manufacture of the active fractions from the plants.

Description

"COMBINATION OF ACTIVE FRACTIONS FROM THE PLANTS
EUPHORBIA TIRUCALU L. AND FICUS CARICA L AND METHOD OF
TREATING CANCER AND AIDS"
FIELD OF THE INVENTION The present invention refers to the combination of active fractions from the plants Euphorbia tirucalli L. e Ficus carica L, more particularly the pharmaceutical compositions comprising the said combinations, which are useful for treatment of cancer and Acquired Immunodeficiency Syndrome (AIDS). The present invention also relates to the process of manufacture of the active fractions from the plants.
BACKGROUND OF THE INVENTION
Since the sprouting of the AIDS and the cancer the constant development of new methods of treatment and new drugs comes significantly drawing out the life of the patients for difficult the evolution of both illnesses. The medicaments used in the treatment of the AIDS postpone the beginning of the illness decelerating the rhythm of the reduction of the cells CD4. But, still thus, they are incapable to cure the illness. Four main types of drugs exist, that act in different phases of the illness: entrance inhibitors, reverse transcriptase nucleosides and non-nucleosides inhibitors and protease inhibitors. Some of these medicines must be managed of agreed form. Generally at least three drugs of two different categories are used simultaneously.
In the same way, many searches are being carried out for the development of new treatments for cancer. The conventional treatments include surgery, radiotherapy, chemotherapy and some drugs administration.
However, the available treatments for AIDS or Cancer therapy provide accented collateral effects to the patients, either of clinical nature, such as nausea, vomit, headache, fatigue, spots in the skin, sleeplessness, stomach ache, muscular problems in the liver, pancreas and nerves, wounds in the mouth, inflammation, anemia, pains and weakness, or of psychological nature, such as the physical mutilation with the withdrawal organs, or with the fall of hair when the utilization of radiotherapy and/or chemotherapy. Thus, it is desired the development of new therapies that do not provide the collaterals effects described above. -
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to the combination of active fractions from the plants Euphorbia turicalli L. and Ficus carica L, useful for treating cancer and AIDS, which not causes physicals and/or psychological damages to patients.
The Euphorbia turicalli L is a member of the Euphorbiaceae family, native from Oriental Africa and Asia, also known as "aveloz", "esquleto",
"graveto de cao", "dedo do diabo", "espinho italiano" Sao Sebastiao tree, petroleum plant, milkbush, pencil tree, finger tree, Indian tree spurge, milkhedge, rubber euphorbia, euphorbe antivenerien, among other. The plant includes the following chemical compounds: 12-o-(2Z)(4E)-octadienol-4- deoxyphorbol-13-acetate, 3,3'-di-o-methylellagic-acid, beta-sitosterol, citric acid, ellagic acid, euphol, euphorone, glucose, hentriacontane, hentriacontanol, isoeuphoral, kamepferol, malic acid, resin, sapogenine acetate, succinic acid, taraxasterol, taraxerin and tirucallol.
The latex obtained from the plant Euphorbia tirucalli L is toxic, irritant and caustic. The sap milky can cause lesion and edema on skin and mucous, irritation, eyes tearingly, edema of eyelids and even though vision difficult. The latex ingestion may also cause nausea, vomits, diahea and some amounts can be fatal.
Ficus carica L is a member of the Moraceae family, native from Asia (Mediterranean region), also called fig and "figo roxo". The plant includes the following chemical compounds: araquidic acid, ascorbic acid, boric acid, citric acid, fumaric acid, glutamic acid, linoleic acid, linolenic acid, malic acid, oleic acid, oxalic acid, pantothenic acid, quinic acid, succinic acid, arabinose, arginine, carbohydrates, beta-carotene, chlorophyll cystin, fitosterols, fructose, glycine, glucose, histidine, isoleucine, leucine, lutein, mucilage, pectin, protein, riboflavin, mineral salts (boron, calcium, copper, phosphorus, potassium and zinc), serine, sucrose, valine, vitamin B6 and the leafs contain furanocumarines.
Process for the manufacture of the active fractions from the plants
Euphorbia tirucalli L and Ficus carica L. according to the invention comprise the steps: a) dissolution of the latex obtained from Euphorbia tirucalli L in water until the concentrations of about 1 ppm to about 10,000 ppm at neutral pH; b) decoction of the leafs from Ficus carica L in water until the concentrations of about 0.1 to about 10%, preferably about 2,5%, inducing and keeping the heating until the temperature of about 70 to 1000C for about 20 to 30 minutes and after cooling by a natural or induced process; c) filtering the product of b) to remove the impurities or solid residues; d) dissolution of the product of c) until concentrations of about 20% to about 40%, preferably about 30% at little acid pH; and e) mixing the active fraction obtained in a) and d) steps.
The active fractions obtained by (1) and (2) are combined in ratio ranges varying from about 2:1 to about 2:100 or from about 2:1 to about 100:1 respectively and should comprise pH limits varying from about 2 for the concentrated product to about 7 for the diluted product. The active fractions combined according to the invention are useful in the treatment of Cancer and AIDS and present analgesic activity, antioxidant, anti-inflammatory, anti rheumatic, emetic, immunessupressor, rubefacient, hipoglicemiant, expectorant, digestive and depurative. Moreover, it can be used internally against scorpions and snakes bites and externally in warts, rheumatic ache, physical damages, asthma, cough, and insects repellent.
Moreover, the combination of active fractions according to the invention does not present adverse effects of the plant Euphorbia tirucalli L. The combined product also provides the acceleration of the treatment process if compared to the traditional treatments.
The present invention also describes pharmaceutical compositions comprising at least one of the active fractions of the plants Euphorbia tirucalli L and Ficus carica L. or their combination together with pharmaceutical acceptable carriers.
The pharmaceutical compositions according to the present invention may contain about 0.001% to about 5% by weight of the active fraction from Euphorbia tirucalli L and about 0.001% to about 50% by weight of the active fraction of Ficus carica L..
The compositions according the present invention may be administered by orally (immediate or sustained release forms), parenterally
(intramuscular, endovenous, intraarteral, intraperitoneal, intrathecal, subcutaneous, hypodermic or intradermic forms), mucosally (pulmonary, sublingual, nasal, conjuctival, rectal or vaginal formsmucosally) or topically.
The appropriated forms includes all the forms known in the art, such as solutions, suryps, suspension, emulsion, lotion, cream, gel, aerosol, tablet, capsule, pellets and other.
The pharmaceutical acceptable carriers according to the invention may include all known in the art, such as lactose, glucose, methyl cellulose, magnesium stearare, dicalcium phosphate, calcium sulphate, manitol, sorbitol, ethanol, glycerol, water and similar.
The composition according to the invention may include as necessary one or more pharmaceutical additives, such as agglutinants, lubrificants, desintegrants agents, color agents and other.
The present invention refers to the use of the combination of active fractions in the manufacture of a medicament or pharmaceutical composition useful in treatment of cancer or AIDS.
The present invention also refers to the method of treating cancer and AIDS by the administration of the combination of active fractions from the plants Euphorbia tirucalli L and Ficus carica L. or the administration of the pharmaceutical compositon comprising said active fractions mentioned above. The following example illustrates a particular embodiment of the invention without any limitation.
EXAMPLES
The active fraction of Euphorbia tirucalli L was gotten becoming fluid 0,5ml of the latex extracted of the plant in 1 liter of water (concentration of the solution 436,35ppm, or either, 0,43635g of the latex for one 1 kg of solution). pH measured in the diluted product was 7,12.
The active fraction of Ficus carica L was prepared weighing initially 25g of leves of the related plant, placing them on decoction in 1 liter of water until the temperature of 700C and remaining superior temperature 700C for about 25 minutes (maximum temperature reached 98-1000C). After that the gotten cool and filtered product. The gotten intent product then was diluted with water 30% (300 ml_ of product concentrated for 1 liter of water). pH measured in the diluted product was of 5,43.
The gotten fractions later had been combined.

Claims

1. Combination of active fractions from the plants Euphorbia tirucalli L. and Ficus carica L comprising at least the 12-o-(2Z)(4E)-octadienol- 4-deoxyphorbol-13-acetate, 3,3'-di-o-methylellagic-acid, beta-sitosterol, citric acid, ellagic acid, euphol, euphorone, glucose, hentriacontane, hentriacontanol, isoeuphoral, kamepferol, malic acid, resin, sapogenine acetate, succinic acid, taraxasterol, taraxerin, tirucallol into the active fraction of Euphorbia tirucalli L and at least the araquidic acid, ascorbic acid, boric acid, citric acid, fumaric acid, glutamic acid, linoleic acid, linolenic acid, malic acid, oleic acid, oxalic acid, pantothenic acid, quinic acid, succinic acid, arabinose, arginine, carbohydrates, beta-carotene, chlorophyll cystin, fitosterols, fructose, glycine, glucose, histidine, isoleucine, leucine, lutein, mucilage, pectin, protein, riboflavin, mineral salts (boron, calcium, copper, phosphorus, potassium and zinc), serine, sucrose, valine, vitamin B6 and furanocumarines into the active fraction of Ficus carica L
2. Combination according to claim 1 comprising active fractions of Euphorbia tirucalli L. and Ficus Carica L in ratio ranges varying from about 2:1 to about 2:100 or from about 2:1 to about 100:1.
3. Combination according to claims 1 to 2 wherein the pH varies from about 2 to about 7.
4. Use of the combination as defined in claims 1 to 3 in the manufacture of a medicament useful in treatment of cancer or AIDS.
5. Pharmaceutical composition comprising the combination of active fractions from the plants Euphorbia tirucalli L. and Ficus carica L together with at least a pharmaceutical acceptable carrier.
6. Pharmaceutical composition according to claim 5 comprising from about 0,001 % to about 5 % by weight of an active fraction from Euphorbia tirucalli L and from about 0,001 % to about 50 % by weight of an active fraction 8
from Ficus carica L.
7. Pharmaceutical composition according to claims 5 to 6 wherein said composition is intended to be administered orally, parenterally, mucosally or topically.
8. Pharmaceutical composition according to claim 7 wherein the said composition is intended to " be" administered orally by immediate or sustained release forms.
9. Pharmaceutical composition according to claim 7 wherein the said composition is intended to be administered parenterally by intramuscular, endovenous, intraarteral, intraperitoneal, intrathecal, subcutaneous, hypodermic or intradermic forms.
10. Pharmaceutical composition according to claim 7 wherein the said composition is intended to be administered mucosally by pulmonary, sublingual, nasal, conjuctival, rectal or vaginal forms.
11. Use of the pharmaceutical composition as defined in claims 5 to 10 in the manufacture of a medicament useful in treatment of cancer or AIDS.
12. Process for the preparation of active fraction from the plants Euphorbia tirucalli L. and Ficus carica L. comprising the steps: a) dissolution of the latex obtained from Euphorbia tirucalli L. in water until the concentrations of about 1 ppm to about 10,000 ppm at neutral pH; b) decoction of the leafs from Ficus carica L in water until the concentrations of about 0.1 to about 10%, preferably about 2,5%, inducing and keeping the heating until the temperature of about 70 to 1000C for about 20 to 30 minutes and after cooling by a natural or induced process; c) filtering the product of b) to remove the impurities or solid residues; d) dissolution of the product of c) until concentrations of about 20% to about 40%, preferably about 30% at little acid pH; and e) mixing the active fraction obtained in a) and d) steps.
13. Method of treating cancer and AIDS comprising the administration of the combination of active fractions from the plants Euphorbia tirucalli L. and Ficus carica L as defined in claims 1 to 3.
14. Method of treating cancer and AIDS comprising the administration of the pharmaceutical composition including the combination of active fractions from the plants Euphorbia tirucalli L and Ficus carica L as defined in claims 5 to 10.
PCT/BR2004/000127 2004-07-21 2004-07-21 Combination of active fractions from the plants euphorbia tirucalli l and ficos carica l. and method of treating cancer and aids WO2006007676A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/BR2004/000127 WO2006007676A1 (en) 2004-07-21 2004-07-21 Combination of active fractions from the plants euphorbia tirucalli l and ficos carica l. and method of treating cancer and aids

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/BR2004/000127 WO2006007676A1 (en) 2004-07-21 2004-07-21 Combination of active fractions from the plants euphorbia tirucalli l and ficos carica l. and method of treating cancer and aids

Publications (1)

Publication Number Publication Date
WO2006007676A1 true WO2006007676A1 (en) 2006-01-26

Family

ID=35784824

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2004/000127 WO2006007676A1 (en) 2004-07-21 2004-07-21 Combination of active fractions from the plants euphorbia tirucalli l and ficos carica l. and method of treating cancer and aids

Country Status (1)

Country Link
WO (1) WO2006007676A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006112716A2 (en) * 2005-04-21 2006-10-26 N.V. Nutricia Nutritional supplement for hiv patients
WO2010015874A1 (en) * 2008-08-05 2010-02-11 Amazonia Fitomedicamentos Ltda Pharmaceutical uses of lanosta-8,24-dien-3-ols
WO2010019864A2 (en) * 2008-08-14 2010-02-18 Ullman Medical, Inc. Ficus extracts having angiogenesis inhibiting activity and methods of isolating and using the same
WO2011086424A1 (en) * 2010-01-15 2011-07-21 Amazonia Fitomedicamentos Ltda Pharmaceutical use of multicyclic compounds mixtures as concomitant anti-cancer, anti-inflammatory and anti-pain agents
WO2011086423A1 (en) * 2010-01-15 2011-07-21 Amazonia Fitomedicamentos Ltda Pharmaceutical use of multicyclic compounds as anti-aids agents
US8252769B2 (en) 2004-06-22 2012-08-28 N. V. Nutricia Intestinal barrier integrity
US8277836B2 (en) 1998-08-11 2012-10-02 N.V. Nutricia Carbohydrates mixture
WO2014066967A1 (en) * 2012-11-01 2014-05-08 Amazônia Fitomedicamentos Ltda. Ingenol-derived compounds that can be used for treating cancer
US10426791B2 (en) 2004-05-17 2019-10-01 N.V. Nutricia Synergism of GOS and polyfructose
WO2023147640A1 (en) * 2022-02-07 2023-08-10 GERVÁSIO ALVES DA SILVA, Társis Preparation of novel triterpene alcohol derivatives with enhanced bioavailability for cancer, inflammation and pain treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0202733A (en) * 2002-04-03 2004-05-11 Amazonia Fitomedicamentos Ltda Herbal extract compositions from plant species euphorbia tirucalli l. and ficus carica l

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0202733A (en) * 2002-04-03 2004-05-11 Amazonia Fitomedicamentos Ltda Herbal extract compositions from plant species euphorbia tirucalli l. and ficus carica l

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580295B2 (en) 1998-08-11 2013-11-12 N.V. Nutricia Carbohydrates mixture
US8277836B2 (en) 1998-08-11 2012-10-02 N.V. Nutricia Carbohydrates mixture
US9763466B2 (en) 1998-08-11 2017-09-19 N.V. Nutricia Carbohydrates mixture
US10426791B2 (en) 2004-05-17 2019-10-01 N.V. Nutricia Synergism of GOS and polyfructose
US10499676B2 (en) 2004-06-06 2019-12-10 N.V. Nutricia Intestinal barrier integrity
US9084433B2 (en) 2004-06-06 2015-07-21 N. V. Nutricia Intestinal barrier integrity
US11076623B2 (en) 2004-06-22 2021-08-03 N.V. Nutricia Intestinal barrier integrity
US8252769B2 (en) 2004-06-22 2012-08-28 N. V. Nutricia Intestinal barrier integrity
WO2006112716A3 (en) * 2005-04-21 2007-05-10 Nutricia Nv Nutritional supplement for hiv patients
WO2006112716A2 (en) * 2005-04-21 2006-10-26 N.V. Nutricia Nutritional supplement for hiv patients
WO2010015874A1 (en) * 2008-08-05 2010-02-11 Amazonia Fitomedicamentos Ltda Pharmaceutical uses of lanosta-8,24-dien-3-ols
RU2476226C2 (en) * 2008-08-05 2013-02-27 Амазония Фитомедикаментос Лтда Pharmaceutical applications of lanost-8,24-dien-3-ols
CN102112133B (en) * 2008-08-05 2013-05-08 阿马佐尼亚菲托药品有限公司 Pharmaceutical uses of lanosta-8, 24-dien-3-ols
US9238036B2 (en) 2008-08-05 2016-01-19 Amazonia Fitomedicamentos Ltda Pharmaceutical uses of lanosta-8,24-dien-3-ols
AU2008360329B2 (en) * 2008-08-05 2014-07-31 Amazonia Fitomedicamentos Ltda Pharmaceutical uses of lanosta-8,24-dien-3-ols
KR101496507B1 (en) * 2008-08-05 2015-03-03 아마조니아 피토메디카멘토스 엘티디에이 Pharmaceutical uses of lanosta-8,24-dien-3-ols
US9066959B2 (en) 2008-08-14 2015-06-30 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Ficus extracts having angiogenesis inhibiting activity and methods of isolating and using the same
WO2010019864A3 (en) * 2008-08-14 2010-05-27 Ullman Medical, Inc. Ficus extracts having angiogenesis inhibiting activity and methods of isolating and using the same
WO2010019864A2 (en) * 2008-08-14 2010-02-18 Ullman Medical, Inc. Ficus extracts having angiogenesis inhibiting activity and methods of isolating and using the same
WO2011086423A1 (en) * 2010-01-15 2011-07-21 Amazonia Fitomedicamentos Ltda Pharmaceutical use of multicyclic compounds as anti-aids agents
WO2011086424A1 (en) * 2010-01-15 2011-07-21 Amazonia Fitomedicamentos Ltda Pharmaceutical use of multicyclic compounds mixtures as concomitant anti-cancer, anti-inflammatory and anti-pain agents
WO2014066967A1 (en) * 2012-11-01 2014-05-08 Amazônia Fitomedicamentos Ltda. Ingenol-derived compounds that can be used for treating cancer
WO2023147640A1 (en) * 2022-02-07 2023-08-10 GERVÁSIO ALVES DA SILVA, Társis Preparation of novel triterpene alcohol derivatives with enhanced bioavailability for cancer, inflammation and pain treatment

Similar Documents

Publication Publication Date Title
US10568944B2 (en) Treatment of rosacea with compositions containing bromelain
BG64522B1 (en) Device for the treatment of viral infectiuous diseases
JPH08500092A (en) Dermatological composition
US20030157185A1 (en) Topical treatment of neuropathy
US7871647B1 (en) Topical treatment of neuropathy
WO2006007676A1 (en) Combination of active fractions from the plants euphorbia tirucalli l and ficos carica l. and method of treating cancer and aids
US6455070B1 (en) Composition for treating symptoms of influenza
WO2017036241A1 (en) Acne-removing traditional chinese medicine composition and preparation method thereof
JPH03145427A (en) Pharmaceutical composition having effect on skin microcirculation
ITMI20100953A1 (en) KIT OF PARTS FOR THE TREATMENT AND / OR PREVENTION OF SKIN ULCERS
KR20040026268A (en) Topical composition for lowering pruritus or damaged skin barrier caused by atopic dermatitis
HU203668B (en) Cosmetic containing medicinal plants and process for producing composition against psoriasis
WO2016144196A1 (en) A pharmaceutical and/or cosmetic composition for treating skin diseases and damages, the process for preparing of the pharmaceutical and/or cosmetic composition and its use
KR20030055154A (en) A composition for treating a dermatitis and a method of preparing the same
CN107158051B (en) Tannic acid ointment for treating eczema and preparation method thereof
WO2015168224A1 (en) Synergistic mixture of betamethasone and tranilast with a transdermal gel for scar treatment
CN105343399B (en) A Chinese medicinal composition and ointment for treating skin injury, and preparation method thereof
US9421161B2 (en) Herbal composition and a method of making thereof
CN109223931A (en) A kind of burn cream and preparation method thereof for treating burn
BRPI0706837A2 (en) use of epoxidized compounds
KR20030037355A (en) Preparing method of health care composition helpful for asthma's prevention and treatment and composition therof
CN113713000B (en) Main medicine component composition for treating sore carbuncle, burn, scald and acne, sustained and controlled release pharmaceutical preparation, and preparation method and application thereof
RU2582282C1 (en) Method of producing agent having stress protective and anti-hypoxic activity
JPS61263924A (en) Nasal drop
CN115414415B (en) A Chinese medicinal composition for treating skin injury and ulcer, and its preparation method

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 04737721

Country of ref document: EP

Kind code of ref document: A1